GeneDx shares plunge 19% after Q4 outlook misses Consensus
The genetic testing provider cut full-year growth targets, sending the stock down 10% in after-hours trading before a further drop on Tuesday.
The genetic testing provider cut full-year growth targets, sending the stock down 10% in after-hours trading before a further drop on Tuesday. Published 2026-11-10 by Falling Shares.
| By Falling Shares Intelligence, edited by Wung Thomas, Editor-in-Chief
Written by Falling Shares Intelligence, our automated newsroom, from the public sources listed below and live market data. Every figure is checked against that material before publication, but the story has not been reviewed by a human editor. Check the linked sources before relying on it, and report errors to info@fallingshares.com.
Shares in GeneDx Holdings Corp. fell 18.87% on Tuesday after the genetic testing services provider announced its Q3 2026 results and issued a revenue outlook for Q4 that fell short of consensus estimates. The stock had already dropped 10.2% in after-hours trading on Monday following the initial report.
Q3 results beat but guidance disappoints
GeneDx reported third-quarter revenue of $123.1 million, slightly above the FactSet estimate of $122.9 million. Adjusted earnings per share came in at $0.28, beating the Zacks Consensus Estimate of $0.07. However, the company posted a GAAP loss of $12.3 million.
The market reaction was driven primarily by the company's forward-looking statements. GeneDx issued a revenue outlook for the fourth quarter that missed analyst expectations, signaling slower growth than the market had priced in. This guidance cut triggered the initial 10.2% decline in Monday's after-hours session.
Stock under pressure for months
The latest fall adds to a steep downward trend for the NASDAQ-listed company. GeneDx shares have dropped 17.0% over the past five days and 59.2% over the last year. The stock is currently 66.0% below its 52-week high of $170.87.
Falling Shares rates the stock Unstable, with annualised volatility of 84.5% compared to 14.5% for the benchmark. In the latest session, 13.3% of the move was company-specific, while market and sector factors had negligible impact. The S&P 500 fell 0.5% and the US Health Care sector dropped 0.3% in the same session.